Related Experiment Video

Updated: Feb 10, 2026

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes
11:34

A Simple and Efficient Method for Testing Immunomodulatory Agents for Generation of Tolerogenic Dendritic Cells from Human CD14+ Monocytes

Published on: April 11, 2025

849

Immunomodulatory agents in myelofibrosis

Ali Tabarroki1, Ramon V Tiu

  • 1Taussig Cancer Institute, Cleveland Clinic, Department of Translational Hematology and Oncology Research, Cleveland, OH 44195, USA.

Expert Opinion on Investigational Drugs
|June 7, 2012
PubMed
Abstract

Insights

Immunomodulatory agents (IMiDs) offer alternative myelofibrosis (MF) treatments, managing symptoms like splenomegaly and cytopenias. Newer agents like pomalidomide show promise, potentially becoming frontline anemia therapies in MF.

Area of Science:

  • Hematology
  • Pharmacology
  • Oncology

Background:

  • Myelofibrosis (MF) treatment options are limited, with anemia and constitutional symptoms causing significant morbidity.
  • Current therapies, including JAK2 inhibitors, do not fully address all MF manifestations.
  • Immunomodulatory agents (IMiDs) have shown utility in MF, with newer agents like pomalidomide demonstrating potential.

Purpose of the Study:

  • To review the biological rationale and clinical efficacy of IMiDs in myelofibrosis.
  • To evaluate the role of pomalidomide and potential combination therapies for MF.
  • To explore the use of IMiDs in the context of JAK2 inhibitor treatments.

Main Methods:

  • A literature review was conducted using PubMed, focusing on IMiDs and myelofibrosis.
  • Included studies analyzed the biological mechanisms and clinical outcomes of IMiD use in MF.
  • Relevant clinical studies with over 15 participants were prioritized.

Main Results:

  • IMiDs are effective alternatives for managing splenomegaly and constitutional symptoms in MF patients.
  • These agents continue to be valuable for treating cytopenias associated with myelofibrosis.
  • Pomalidomide demonstrates a notable response in treating anemia, suggesting its potential as a primary therapy.

Conclusions:

  • IMiDs represent a viable treatment option in the JAK2 inhibitor era for specific MF symptoms.
  • Pomalidomide's efficacy in anemia may position it as a frontline treatment choice.
  • Future research may identify molecular biomarkers to predict patient response to IMiDs.

More Related Videos

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices12:04

Assessment of the Cytotoxic and Immunomodulatory Effects of Substances in Human Precision-cut Lung Slices

Published on: May 9, 2018

14.7K
Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs06:20

Assessment of the Immunomodulatory Properties of Human Mesenchymal Stem Cells MSCs

Published on: December 24, 2015

12.9K

Related Concept Videos

Subviral Agents01:29

Subviral Agents

Subviral agents are infectious entities that resemble viruses but lack one or more viral components, such as a capsid or essential replication machinery. These agents include viroids, prions, and satellites, each possessing distinct structural and functional characteristics that influence their mode of infection and replication.Viroids are the simplest subviral agents, consisting of circular, single-stranded RNA molecules without a protein coat. They exclusively infect plants, relying entirely...
583
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
552
Air-entraining Agents01:27

Air-entraining Agents

Air-entraining agents improve the durability and workability of concrete in climates with frequent freezing and thawing. These agents prevent cracks by introducing small air bubbles into the mix, creating spaces accommodating water expansion when temperatures drop. The air-entraining agents lower the surface tension of water, forming stable, small air bubbles. This method is more effective than having accidental large voids, as the intentional, smaller, and evenly distributed air voids improve...
276
Masking and Demasking Agents01:19

Masking and Demasking Agents

EDTA titrations may necessitate masking and demasking agents to temporarily protect a particular metal ion in a mixture from the EDTA reaction. These agents facilitate the sequential analysis of the metal ions by forming stable complexes with some—but not all—metal ions during certain steps.
There are many masking agents, such as cyanide, fluoride, triethanolamine, thiourea, and 2,3-bis(sulfanyl)propan-1-ol (formerly 2,3-dimercapto-1-propanol), with the masking agent chosen based on...
3.6K
Spasmolytic Agents: Chemical Classification01:29

Spasmolytic Agents: Chemical Classification

Spasmolytic agents are drugs used to alleviate muscle spasms and spasticity. They can be categorized into different chemical groups based on their mechanisms of action. Centrally acting spasmolytics primarily affect the spinal cord, while others directly target skeletal muscle cells.
A major class of centrally acting spasmolytics is the α2-agonist, such as tizanidine. These drugs bind to α2-adrenoceptors, inhibiting the release of the excitatory neurotransmitter glutamate. They also...
1.3K
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
681